Lipoprotein(a) in a High-risk Turkish Population Sample: Distribution and Correlations, with Emphasis on Inverse Relationship to Insulinemia in Men;Yüksek Riskli bir Örneklemimizde Lipoprotein (a): Daǧilimi ve Baǧintilari Zemininde Türk Erkeklerinde İnsülinemi ile Ters İlişkisi Gözlemi

Turk Kardiyoloji Dernegi Arsivi

Volumn 32, Issue 2, 2004, Pages 82-90

  Onat, Altan ^a   Uyarel, Hüseyin ^a   Hergenç, Gülay ^a   Yazici, Mehmet ^a   Uzunlar, Bülent ^a   Türkmen, Serdar ^a   Sari, Ibrahim ^a   Can, Günay ^a   Sansoy, Vedat ^a  

^a NONE

Author keywords

Coronary heart disease; Epidemiology; Lipoprotein(a); Metabolic syndrome; Turkish adults

Indexed keywords

APOLIPOPROTEIN A; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY RISK; CORRELATION ANALYSIS; ELECTROCARDIOGRAM; FEMALE; HUMAN; INSULINEMIA; ISCHEMIC HEART DISEASE; LINEAR REGRESSION ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEPHELOMETRY; PREVALENCE; TRIACYLGLYCEROL BLOOD LEVEL; TURKEY (REPUBLIC);

EID: 1642313515     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Berg K: A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963; 59:362-82
2. McLean J, Tomlinson J, Kuang WJ, et al: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132-7
3. Albers JJ, Adolphson JL, Hazzard WR: Radioimmunoassay of Human Plasma Lp(a) Lipoprotein. J Lipid Res 1977; 18: 331-8
4. Marcovina SM, Hegele RA, Koschinsky ML: Lipoprotein(a) and coronary heart disease. Curr Cardiol Rep 1999; 1:105-111
5. Yingdong Z, Xiuling L: Apolipoprotein (a) and cortical cerebral infarction. Chin Med Sci J. 1999; 14:249-54
6. Cheng SW, Ting AC, Wong J: Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 1997; 17:17-23
7. Danesh J, Collins R, Peto R: Lipoprotein a and coronary heart disease: a meta-analysis of prospective studies. Circulation 2000; 102:1082-5
8. Caplice NM, Panetta C, Peterson TE, et al: Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98:2980-7
9. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, Plow EF. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994; 14:438-42
10. Ren S, Man RY, Angel A, Shen GX: Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-I in cultured vascular endothelial cells. Atherosclerosis 1997; 128:1-10
11. Buechler C, Ullrich H, Aslanidis C, et al: Lipoprotein (a) downregulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes. Biochim Biophys Acta 2003; 1642:25-31
12. Fan J, Watanabe T: Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003; 10:63-71
13. Bogavac-Stanojevic N, Djurovic S, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Kalimanovska-Ostric D: Circulating transforming growth factor-beta1, lipoprotein(a) and cellular adhesion molecules in angiographically assessed coronary artery disease. Clin Chem Lab Med 2003; 41:893-8
14. Yashiro A, O'Neil J, Hoff HF: Insoluble complex formation of lipoprotein(a) with low density lipoprotein in the presence of calcium ions. J Biol Chem 1993; 268:4709-15
15. Onat A. Türk yetişkinleri için kullanilmaya elverişli bir koroner risk puanlamasi. Türk Kardiyol Dern Arş 2002; 30:604-11
16. Friedewald WT, Levy J, Fredrickson DS: Estimation of the concentration of low-density-lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-509
17. Rose G, Blackburn H, Gillum RF, Prineas RJ: Cardiovascular Survey Methods, 2nd edn. Geneva, WHO, 1982; 124-127
18. Onat A: Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156:1-10
19. Executive Summary of the third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97
20. American Diabetes Association: Clinical practice recommendations. Diabetes Care 1997; 20:S1-S70
21. Mahley RW, Palaoǧlu KE, Atak Z, et al: Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36:839-859
22. Hergenç G, Özsüllü T, Çetinalp P, Beşoluk Ş, Sönmez B: Lp(a) levels in men with coronary artey occlusion and healthy male controls. Biochem Soc Trans 1999; 27:A1222
23. Adam B, Talu C, Bedir A, Alvur M, Sagkan O: The levels of lipids, lipoproteins and apolipoproteins in healthy people in the central region of the Black Sea. Jpn Heart J 1999; 40:427-34
24. Örem A, Deǧer O, Kulan K, Önder E, Kiran E, Uzunosmanoǧlu D: Evaluation of lipoprotein(a) [Lp(a)] as a risk factor for coronary artery disease in the Turkish population. Clin Biochem 1995; 28:171-3
25. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003; 49:1785-96
26. Duell PB, Hagemenas F, Connor WE: The relationship between serum lipoprotein(a) and insulinemia in healthy nondiabetic adult men. Diabetes Care. 1994; 17:1135-40
27. Haffner SM, Gruber KK, Morales PA, et al: Lipoprotein (a) concentrations in Mexican Americans and non-Hispanic whites: the san Antonio Herat Study. Am J Epidemiol 1992; 136:1061-8
28. Inoue K, Nago N, Matsuo H, et al: Serum insulin and lipoprotein(a) concentrations. Diabetes Care 1997; 20:1242-7
29. Haffner SM, Karhapaa P, Rainwater DL, Mykkanen L, Aldrete G Jr, Laakso M: Insulin sensitivity and lipoprotein(a) concentrations in normoglycemic men. Diabetes Care 1995; 18:193-9
30. Rainwater DL, Haffner SM: Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 1998; 18:1335-41
31. Koschinsky ML, Marcovina SM: The relationship between lipoprotein(a) and the complications of diabetes mellitus. Acta Diabetol 2003; 40:65-76
32. Neele DM, de Eit EC, Princen HM: Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia 1999; 42:897-8
33. Chien K-L, Lee Y-T, Sung F-C, Su T-C, Hsu H-C, Lin R-S. Lipoprotein (a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors. Atherosclerosis 1999; 143:267-73
34. Craig WY, Neveux LM, Palomaki GE, Clevelang MM, Haddow JE: Lipoprotein (a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998; 11:2301-6
35. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS: Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997; 96:1390-7
36. Glader CA, Birgander LS, Stenlund H, Dahlen GH: Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med. 2002; 252:27-35
37. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ: Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995; 274:1771-4
38. Luc G, Bard JM, Arveiler D, et al: PRIME Study Group: Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis. 2002; 163:377-84
39. Cantin B, Gagnon F, Moorjani S, et al: Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31:519-25